Debiopharm Receives Marketing Authorisation From Swissmedic For Moapar

Debiopharm has received marketing authorisation for Moapar 11.25mg, from Swissmedic. Moapar 11.25mg is intended for a reversible reduction of serum testosterone to the level of castration in adult men suffering from sexual deviations.

Repotedly, the company has also signed license agreements for the distribution of Salvacyl/Moapar in nine major European countries – France, Germany, the UK, Sweden, Norway, Denmark, Belgium, the Netherlands, and Finland.

Rolland-Yves Mauvernay, president and founder of Debiopharm, said: We are very pleased that Swissmedic has recognised the potential of treatment of sexual deviations with Moapar. This is an important signal for us, as we move closer to providing an alternative treatment for this controversial disorder. It’s a small market, but we feel that it’s our duty to make this treatment available to the medical profession.